# Coronaire plaquefenotypeveranderingen bij lipidenverlagende therapie en cardiovasculaire events

*geplaatst 2025-07-09 · Cholesterol · Atherosclerosis · doi https://www.atherosclerosis-journal.com/article/S0021-9150(25)01331-0/fulltext · https://hartvaat.nl/2025/07/09/coronaire-plaquefenotypeveranderingen-bij-lipidenverlagende-therapie-en-cardiova/*

De relatie tussen coronaire plaquefenotypeveranderingen op OCT en de afname van ernstige cardiovasculaire events bij lipidenverlagende therapie was onbekend. Deze systematische review en meta-regressie kwantificeerden dit verband.

## English: Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events: a systematic review and meta-regression analysis

This systematic review and meta-regression quantified the relationship between lipid-lowering therapy-induced coronary plaque phenotype changes on OCT and major adverse cardiovascular events. Plaque stabilisation correlated with reduced event rates across therapeutic classes.

## Abstract (original, from the publication)

The specific relationship between changes in coronary plaque phenotype by optical coherence tomography (OCT) and decrease in major adverse cardiovascular events (MACE) among patients receiving lipid-lowering therapies (LLTs) is unknown. Aim was to quantify the relationship between LLTs-related improvement of coronary plaque phenotype (e.g. coronary plaque stabilization, as assessed by OCT) and MACE occurrence.

Auteurs: Giuseppe Patti, Leonardo Grisafi, Danila Azzolina, Luca Cumitini, Domenico D'Amario, Marco Mennuni

---
Bron: Atherosclerosis, https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01331-0/fulltext. Bijgewerkt 2026-07-03T13:25:07Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.